迷雾通加速器最新版-迷雾通官网-迷雾通APP安卓下载-迷雾通VPM

About Us
- About Us
- Board of Directors
- Our Team
Our Science
- Our Science
- Our Pipeline
- Clinical Trials
- Our Scientific Publications & Presentations
- Select References
For Patients
- For Patients
- PNH
- Geographic Atrophy
- C3G
- CAD
- 加速网络连接
Careers
- Careers
- Opportunities
Investors & Media
- Investors & Media
- 加速网络连接
- News Releases
- Perspectives
- Events & Presentations
- 加速网络连接
- Financials & Filings
- Investor FAQs
- Investor Resources
Contact Us
Twitter
LinkedIn

迷雾通加速器最新版-迷雾通官网-迷雾通APP安卓下载-迷雾通VPM

Stock Performance

迷雾通加速器最新版-迷雾通官网-迷雾通APP安卓下载-迷雾通VPM

July 31, 2024 - Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results July 7, 2024 - Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA) July 2, 2024 - Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

迷雾通加速器最新版-迷雾通官网-迷雾通APP安卓下载-迷雾通VPM

Investor Relations:
Argot Partners
Sam Martin / Maghan Meyers
(212) 600-1902
Email: sam@argotpartners.com / maghan@argotpartners.com

Media Relations:
Tracy Vineis
(617) 420-4839
Email: media@apellis.com

迷雾通加速器最新版-迷雾通官网-迷雾通APP安卓下载-迷雾通VPM

Sign up to receive email alerts whenever Apellis Pharmaceuticals, Inc. posts new information to the site. Just enter your email address and click Submit.

加速网络连接 Email Alerts RSS Feeds Contact IR